Within this group, two DNMT inhibitors—5-azacytidine and 5-aza-2-deoxycytidine (or Decitabine)—are approved for treating myelodysplastic syndrome (MDS). This evidence concerns the gene DNMT1 and myelodysplastic syndrome.